Vowst denied as duplicate or overlapping therapy by Blue Cross Blue Shield?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
Blue Cross Blue Shield's specific coverage criteria for vowst are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Blue Cross Blue Shield angle on Vowst
## Why Blue Cross Blue Shield Denied Vowst as "Duplicate Therapy"
Vowst (fecal microbiota, live-jslm) is an FDA-approved microbiome-based therapy for the prevention of recurrent Clostridioides difficile (C. diff) infection. A "duplicate therapy" denial from BCBS means the plan's system identified another medication on your profile that it considers therapeutically equivalent or overlapping — most commonly another microbiome-based product, an antibiotic maintenance regimen, or a probiotic prescription.
This denial category is particularly worth challenging for Vowst because it occupies a specific, FDA-regulated therapeutic class. A generic probiotic supplement or an antibiotic suppression regimen is not a regulatory or clinical equivalent to an FDA-approved live biotherapeutic product.
## Why This Denial Is Appealable
- ACA §2719 external review: After an internal denial, you can request independent external review. An outside clinical reviewer will assess whether the product BCBS identified is genuinely equivalent. The window is typically about four months from the internal denial — note this deadline.
- ERISA §503 (employer plans): BCBS must disclose the specific drug or therapy it considers duplicative and the clinical rationale for that conclusion, giving you a clear target to rebut.
- Expedited review: Available if your clinical situation is urgent (e.g., active or imminent recurrent C. diff).
## Documentation to Gather
- BCBS denial letter: Identify exactly which drug BCBS says is duplicative. Request the written clinical policy if not attached.
- FDA prescribing label for Vowst: Download from DailyMed. Note the specific indication, mechanism, and the patient population for which it is approved.
- Prescriber medical-necessity letter: Your physician should explain why Vowst is not duplicative of the other therapy on file — addressing mechanism of action, regulatory class, and clinical purpose. The letter should also document the C. diff recurrence history.
- C. diff recurrence history: Lab-confirmed episodes with dates, antibiotic treatments used, and outcomes. This establishes medical necessity independent of the duplicate-therapy question.
- Clinical records showing prior C. diff management: Notes documenting the treatment course and why prevention with Vowst is now indicated.
## Criteria-Mapping Approach
| BCBS duplicate-therapy basis | Your response | |---|---| | Identifies Drug X as therapeutically equivalent | FDA label comparison: different mechanism, different regulatory class, different indication | | Claims same clinical purpose | Prescriber letter distinguishing Vowst's role from Drug X | | Policy requires single agent per class | Argument that Vowst is the sole FDA-approved agent in its class for this indication |
## Next Step
File a written internal appeal that directly names the drug BCBS called duplicative and rebuts the equivalence claim point by point. Attach the FDA label, the prescriber letter, and the C. diff history. If the internal appeal fails, external review is your strongest option — independent reviewers apply clinical and regulatory standards, not plan-level formulary logic.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of 17ohp Compounded
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of AAT Augmentation
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Amphetamine Stimulant Prodrug
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Anti Cd 20 Ocrevus